Cannabis valuation methods by license type

The three approaches, and why cannabis bends them

Every business valuation uses some mix of three approaches. Accounting firms that value cannabis companies describe them the same way; see Withum’s February 2026 overview and BeachFleischman’s October 2025 summary.

1. Income approach. Value equals the present worth of future cash flow, through a discounted cash flow model or by capitalizing a single year of normalized earnings. Withum notes that discounted cash flow is often preferred for cannabis because results are volatile and history is short.
2. Market approach. Value is inferred from what comparable companies trade for: guideline public companies, or reported merger and acquisition prices.
3. Asset or cost approach. Value equals assets at fair market value minus liabilities, on either a going-concern or an orderly liquidation basis. BeachFleischman lists both net asset value and net liquidation value under this heading.

Cannabis bends all three. Public comparables are large multi-state operators, not single licenses. Private deal prices are rarely disclosed in full. Cash flow forecasts depend on state-specific prices because product cannot cross state lines. And federal tax under 280E means pre-tax earnings overstate the cash an adult-use owner keeps. Those problems hit each license type differently, which is why the primary method changes.

Which method fits which license?

License type	Primary method	Main cross-check	The number buyers test first
Dispensary or retail	Multiple of normalized EBITDA or SDE	Revenue multiple; after-tax cash	Sales reconciled to track-and-trace and deposits
Cultivation	Earnings at current wholesale prices	Facility and equipment value; price per square foot of canopy	All-in cost per pound against today’s wholesale price
Manufacturing and extraction	Multiple of EBITDA, split by brand, white-label, and tolling revenue	Equipment and compliant build-out value	Customer concentration and gross margin per unit
Distribution and transport	Multiple of EBITDA	Receivables and fleet value	Receivables aging and customer concentration
Delivery	Multiple of EBITDA or SDE	Revenue per order, customer file	Repeat-order rate and driver cost per delivery
Testing lab	Multiple of EBITDA	Instrument value; accreditation status	Client concentration and regulator audit history
Vertically integrated	Sum of the parts	Blended multiple against public operators	Intercompany pricing restated to market
Pre-revenue or provisional license	Scarcity and replacement cost	Risk-adjusted forecast	Whether the license is transferable, and to whom
Ancillary (non-plant-touching)	Ordinary small-business EBITDA or SDE multiples	Customer exposure to cannabis credit risk	Receivables from licensed operators

No published survey gives private-deal multiples for each row. Where this site quotes a figure, it is a dated public data point from a named source, not an appraisal.

Retail: a multiple of verified earnings

Retail has the most stable earnings in the industry, so it is the license most often priced on a multiple. The public anchor is Viridian Capital’s November 2025 report of a median 5.1x enterprise value to 2026 EBITDA for 11 larger U.S. multi-state operators. A single store lacks their scale and liquidity and usually prices below that. Reported 2025 and 2026 deals, and the difference between SDE and EBITDA, are on the page covering dispensary valuation multiples. The license hub for dispensaries covers operations.

Two adjustments are particular to retail. First, 280E lands hardest here because rent, payroll, and security are selling costs; the arithmetic is on the page about how 280E affects valuation. Second, much of a store’s value is the address. A short lease or uncertain landlord consent cuts the multiple, as explained under how real estate control affects value.

Cultivation: earnings, but only at today’s prices

A grow is valued on earnings when it has them, and on its facility when it does not. The reason is price. Colorado’s Department of Revenue set its average market rate for retail flower at $1,721 per pound for early 2021 and $607 for April to June 2026. A grower with a $650 cash cost made money at the first price and loses money at the second.

So the first test is cost per pound against current wholesale, the second is what the building, power, and equipment are worth, and only then does an earnings multiple apply. Per-square-foot and per-pound shortcuts are explained, with their limits, on the page about cultivation valuation per square foot and per pound.

Manufacturing and extraction: three businesses under one license

A processor may run its own brand, make product for other brands, and process other people’s biomass for a fee. Each stream has a different margin and a different risk of walking out the door. A valuation that applies one multiple to the total misses this. The equipment and the classified extraction room also have value separate from earnings, but only to a buyer who can use them in place. See manufacturing and extraction valuation.

Distribution, delivery, and labs: concentration decides the multiple

These licenses sell services to other licensees, or in the case of delivery, to consumers without a storefront. There is no reliable public multiple for any of them. What a buyer’s analysis turns on:

• Distribution. Receivables from retailers are the main asset and the main risk. Aged receivables from struggling stores are written down before any multiple is applied.
• Delivery. No protected address, so the customer file, repeat-order rate, and cost per delivery carry the value.
• Testing labs. Revenue depends on a small number of cultivator and processor clients, and on keeping accreditation. A regulator action against a lab can end the business, so compliance history matters more here than anywhere.

Vertically integrated groups: sum of the parts

Value each segment as if it stood alone, then add. Before doing so, restate internal transfers at market wholesale prices. A group that transfers flower to its own stores at cost shows inflated retail profit and an unprofitable farm, or the reverse. Either distorts both the segment values and the 280E picture, since the split between cost of goods sold and selling expense drives federal tax.

Licenses with no revenue

With no earnings there is nothing to multiply. The test is whether a buyer could get the same license from the state for a filing fee. If yes, value is close to sunk cost. If not, scarcity supports a price, discounted for build-out cost, time, and approval risk. Reported prices are on the page about license value in capped vs uncapped states, and the method is on valuing a pre-revenue license.

Adjustments that apply to every license type

Whatever the primary method, four adjustments follow.

1. Federal tax posture. Adult-use remains Schedule I and subject to 280E. Marijuana under a state medical license moved to Schedule III on 28 April 2026. Show medical and adult-use earnings separately.
2. Transferability. A price means nothing if the regulator will not approve the buyer. Holding periods, residency rules, and ownership caps shrink the buyer pool.
3. Liabilities that follow the license or the entity. Unpaid excise tax, unfiled returns, and open violations come off the price.
4. Structure. A headline price paid in seller notes or thinly traded stock is worth less than the same figure in cash.

The cannabis business valuation overview ties these together, and the worked examples run the arithmetic for a store, a grow, and a bare license. This page is educational. It is not an appraisal, and it is not tax or legal advice.